CD38 and Miyoshi myopathy: The advancement of new and targeted regimens for MM therapy, including proteasome inhibitors, immunomodulators, and monoclonal antibodies (CD38 monoclonal antibody, etc.)as well as autologous stem cell transplantation (ASCT), has effectively improved patient outcomes and prolonged MM survival [4].